AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $944,000 | +317.7% | 18,665 | +284.8% | 0.00% | – |
| Q2 2023 | $226,000 | +78.0% | 4,850 | +45.9% | 0.00% | – |
| Q1 2023 | $127,000 | -56.5% | 3,325 | -37.4% | 0.00% | – |
| Q4 2022 | $292,000 | +228.1% | 5,312 | +103.9% | 0.00% | – |
| Q3 2022 | $89,000 | +304.5% | 2,605 | +9.9% | 0.00% | – |
| Q2 2022 | $22,000 | -58.5% | 2,370 | -37.5% | 0.00% | – |
| Q1 2022 | $53,000 | -67.1% | 3,793 | -50.2% | 0.00% | – |
| Q4 2021 | $161,000 | +66.0% | 7,623 | +74.6% | 0.00% | – |
| Q3 2021 | $97,000 | -2.0% | 4,365 | +9.9% | 0.00% | – |
| Q2 2021 | $99,000 | +28.6% | 3,972 | +49.8% | 0.00% | – |
| Q1 2021 | $77,000 | +60.4% | 2,652 | +44.8% | 0.00% | – |
| Q4 2020 | $48,000 | +41.2% | 1,831 | +67.8% | 0.00% | – |
| Q3 2020 | $34,000 | +25.9% | 1,091 | 0.0% | 0.00% | – |
| Q2 2020 | $27,000 | +12.5% | 1,091 | -4.3% | 0.00% | – |
| Q1 2020 | $24,000 | +41.2% | 1,140 | +53.2% | 0.00% | – |
| Q4 2019 | $17,000 | +1600.0% | 744 | +1590.9% | 0.00% | – |
| Q3 2019 | $1,000 | – | 44 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| University of Wisconsin Foundation | 103,816 | $5,251,013 | 6.02% |
| Boxer Capital, LLC | 1,676,733 | $84,809,155 | 4.52% |
| Redmile Group, LLC | 1,769,684 | $89,510,617 | 4.26% |
| Ghost Tree Capital, LLC | 250,000 | $12,645,000 | 4.16% |
| Logos Global Management LP | 600,000 | $30,348,000 | 4.05% |
| COMMODORE CAPITAL LP | 565,000 | $28,577,700 | 3.34% |
| Yiheng Capital Management, L.P. | 1,221,674 | $61,792,271 | 3.15% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,000 | $10,116,000 | 3.07% |
| Atlas Venture Life Science Advisors, LLC | 359,251 | $18,170,915 | 2.81% |
| Perceptive Advisors | 1,619,425 | $81,910,517 | 2.73% |